chartexchange

Why This IPO Stock, An AnaptysBio Spinoff, Just Surged

Investor's Business Daily | Oct 12, 2026 9:27 AM EDT

First Tracks Biotherapeutics posted "impressive" results for its celiac disease treatment Monday, and the IPO stock surged.
The post Why This IPO Stock, An AnaptysBio Spinoff, Just Surged appeared first on Investor's Business Daily .

Read original article